SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-048084
Filing Date
2022-04-21
Accepted
2022-04-21 08:00:17
Documents
8
Period of Report
2022-05-25

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm223451-2_def14a.htm DEF 14A 1960999
2 GRAPHIC lg_adaptimmune-4clr.jpg GRAPHIC 39476
3 GRAPHIC tm223451d2-pc_ceobwlr.jpg GRAPHIC 40719
4 GRAPHIC tm223451d2-pc_otherneobwlr.jpg GRAPHIC 51536
5 GRAPHIC tm223451d2-lc_share4clr.jpg GRAPHIC 198861
6 GRAPHIC tm223451d2-bc_ceo4clr.jpg GRAPHIC 117334
7 GRAPHIC tm223451d2-px_01proxybwlr.jpg GRAPHIC 1013459
8 GRAPHIC tm223451d2-px_02proxybwlr.jpg GRAPHIC 592756
  Complete submission text file 0001104659-22-048084.txt   4788309
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37368 | Film No.: 22839696
SIC: 2836 Biological Products, (No Diagnostic Substances)